Jasper Therapeutics to Present at Cantor Fitzgerald’s The Future of Oncology Virtual Symposium
REDWOOD CITY, Calif., March 31, 2023 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (NASDAQ: JSPR), a…
REDWOOD CITY, Calif., March 31, 2023 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (NASDAQ: JSPR), a…
REDWOOD CITY, Calif., March 31, 2023 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (NASDAQ: JSPR), a…
David Southwell steps down; Gavin MacBeath, Ph.D., Chief Scientific and Operating Officer, to serve as…
David Southwell steps down; Gavin MacBeath, Ph.D., Chief Scientific and Operating Officer, to serve as…
OREM, Utah, March 31, 2023 (GLOBE NEWSWIRE) — Reflect Scientific Inc (OTCQB: RSCF), a provider…
OREM, Utah, March 31, 2023 (GLOBE NEWSWIRE) — Reflect Scientific Inc (OTCQB: RSCF), a provider…
• 2022 Product Revenue Increased to $54.1 Million, Up 13% over 2021 • Global End User…
• 2022 Product Revenue Increased to $54.1 Million, Up 13% over 2021 • Global End User…
Media Release Efti plus pembrolizumab achieved mOS of 9.9 months and a 39% OS rate…
Media Release Efti plus pembrolizumab achieved mOS of 9.9 months and a 39% OS rate…
— Completed business combination with FLAC and closed concurrent, oversubscribed approximately $235 million PIPE, led…
— Completed business combination with FLAC and closed concurrent, oversubscribed approximately $235 million PIPE, led…
If subsequently approved, Entresto will be the first and only approved therapy for the treatment…
If subsequently approved, Entresto will be the first and only approved therapy for the treatment…
NEW YORK, March 31, 2023 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that the…
NEW YORK, March 31, 2023 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that the…
DURHAM, N.C., March 31, 2023 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or “the…
DURHAM, N.C., March 31, 2023 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or “the…
Instil confirms cash runway beyond 2026 ITIL-306 phase 1 study anticipated to receive CTA clearance…
Instil confirms cash runway beyond 2026 ITIL-306 phase 1 study anticipated to receive CTA clearance…